DTC — Defence Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- CA$50.45m
- CA$51.10m
Annual balance sheet for Defence Therapeutics, fiscal year end - June 30th, CAD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 5.45 | 0.507 | 2.79 | 0.057 | 1.23 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.072 | 0.028 | 0.15 | 0.097 | 0.198 |
| Prepaid Expenses | |||||
| Total Current Assets | 5.56 | 0.674 | 3.43 | 0.214 | 1.46 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | — | — | 0.059 | 0.264 | 0.188 |
| Net Intangible Assets | |||||
| Total Assets | 5.61 | 0.72 | 3.53 | 0.478 | 1.65 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 0.122 | 1.11 | 0.22 | 4.05 | 2.91 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.122 | 1.11 | 1.97 | 4.06 | 2.91 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 5.49 | -0.388 | 1.57 | -3.58 | -1.26 |
| Total Liabilities & Shareholders' Equity | 5.61 | 0.72 | 3.53 | 0.478 | 1.65 |
| Total Common Shares Outstanding |